Subscription, allocation and payment

The Rights Issue was subscribed to approximately SEK 2.2 million including pre-subscription commitments of approximately SEK 2.0 million, which corresponds to a subscription rate of approximately 54.8 percent. ODI is provided approximately SEK 2.2 million before transaction related costs of approximately SEK 0.6 million.

A total of 494,684 shares were subscribed for with the support of pre-emptive subscription rights, including pre-subscription commitments. In total, 200,350 shares were subscribed for without the support of pre-emptive subscription rights. Through the Rights Issue, 695,034 new shares will be issued. The subscribers who are allocated shares without preferential rights will receive settlement notes, which are planned to be sent out tomorrow, after a formal board decision on allocation. Allotted shares without pre-emptive right shall be paid in accordance with the instructions on the settlement note.

To cover any potential over-allotment in connection with the Rights Issue, the Company had the option to issue additional shares amounting to up to approximately SEK 2.0 million (the "Over-Allotment Option"). The Over-Allotment Option has not been exercised and is not intended to be exercised in connection with the Rights Issue.

Number of shares and share capital

When the Rights Issue has been registered with the Swedish Companies Registration Office, the total number of shares will have increased by 695,034 shares, from 15,220,000 shares to 15,915,034 shares, the Company's share capital will, upon registration, have increased by approximately SEK 27,801.36, from approximately SEK 608,800.00 to SEK 636,601.36. The shareholders who have not participated in the Rights Issue will be subject to a dilution effect corresponding to approximately 4.4 percent of the votes and capital.

Trading in BTA

Trading in BTA's will take place on Spotlight Stock Market until the Rights Issue has been registered with the Swedish Companies Registration Office. The registration is expected to take place around December 27, 2024.

Advisors

In connection with the Rights Issue, ODI Pharma AB has engaged Sedermera Corporate Finance AB as financial advisor, Foyen Advokatfirma i Sverige KB as legal advisor and Nordic Issuing AB as issuing agent.

For further information about the Rights Issue, please contact:

Sedermera Corporate Finance AB

Phone: +46 (0)40 615 14 10

E-mail: cf@sedermera.se

www.sedermera.se

For more information about the Company, please contact:

Volker Wiederrich, Chairman, ODI Pharma AB

E-mail: info@odipharma.com

Important information

This press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, subscription rights, BTAs or other securities in ODI Pharma AB. Investors should not subscribe for or acquire any securities other than on the basis of the information in the memorandum which was made public on November 25, 2024.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or in any other jurisdiction where the distribution of this press release would be unlawful. Nor does this press release constitute an offer to sell new shares, subscription rights, BTAs or other securities to any person in a jurisdiction where it would not be permitted to make such an offer to such a person or where such action would require prospectus, additional registration or other measures than under Swedish law. The memorandum, the application form and other documents relating to the Rights Issue may not be distributed in or into any country where such distribution or the Rights Issue requires measures referred to in the previous sentence or where they would be contrary to the rules of such country. Actions contrary to this instruction may constitute a violation of applicable securities laws.

Neither shares, subscription rights, BTAs nor any other securities have been or will be registered under the United States Securities Act of 1933 in its current wording (the "Securities Act") or the securities laws of any state or other jurisdiction in the United States and may not be offered, subscribed for, exercised, pledged, sold, resold, assigned, delivered or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.

This press release may contain certain forward-looking statements that reflect the Company's current views on future events and financial and operational development. Words such as "intends", " estimates", "expects", "may", "plans", "believes", " anticipates" and other expressions that imply indications or predictions of future developments or trends, and that are not based on historical facts, constitute forward-looking statements. By nature, forward-looking statements involve known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or developments, and actual outcomes may differ materially from those expressed in forward-looking statements. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or the rules of Spotlight Stock Market.

About ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.